Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Genetron Holdings stock price, quote, forecast and news

GTH
US37186H1005
A2P661

Price

29.09 CNY
Today +/-
+0 CNY
Today %
+0 %
P

Genetron Holdings stock price

CNY
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Genetron Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Genetron Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Genetron Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Genetron Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Genetron Holdings Stock Price History

DateGenetron Holdings Price
3/28/202429.09 CNY
3/27/202429.05 CNY

Genetron Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Genetron Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genetron Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genetron Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Genetron Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Genetron Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Genetron Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genetron Holdings’s growth potential.

Genetron Holdings Revenue, EBIT and net profit per share

DateGenetron Holdings RevenueGenetron Holdings EBITGenetron Holdings Net Income
2026e1.36 B CNY-396.22 M CNY-868.45 M CNY
2025e1.11 B CNY-380.52 M CNY-562.17 M CNY
2024e904.47 M CNY-388.92 M CNY-388.35 M CNY
2023e730.82 M CNY-507.92 M CNY-508.55 M CNY
2022650.7 M CNY-703.6 M CNY-808.4 M CNY
2021532 M CNY-532.7 M CNY-496.2 M CNY
2020424.5 M CNY-256.8 M CNY-3.07 B CNY
2019323.4 M CNY-306.6 M CNY-676 M CNY
2018225.2 M CNY-239.4 M CNY-465 M CNY
2017101 M CNY-154.1 M CNY-420.6 M CNY

Genetron Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CNY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M CNY)EBIT (M CNY)EBIT MARGIN (%)NET INCOME (M CNY)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2017201820192020202120222023e2024e2025e2026e
0.10.230.320.420.530.650.730.91.111.36
-122.7743.5631.2725.4722.1812.3123.8423.1221.92
25.7440.8944.8961.3263.5343.23----
26921452603382810000
-154-239-306-256-532-703-507-388-380-396
-152.48-106.22-94.74-60.38-100.00-108.15-69.45-42.92-34.14-29.18
-420-465-676-3,069-496-808-508-388-562-868
-10.7145.38353.99-83.8462.90-37.13-23.6244.8554.45
30.237.941.6100.5153.5154.70000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Genetron Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Genetron Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B CNY)RECEIVABLES (M CNY)OTHER REC. (M CNY)INVENTORIES (M CNY)OTHER CURRENT LIAB. (M CNY)CURRENT ASSETS (B CNY)TANGIBLE ASSETS (M CNY)LONG-T. INVEST. (M CNY)LONG-T. REC. (M CNY)INTANGIBLE ASSETS (M CNY)GOODWILL (M CNY)OTHER NON-CURRENT ASSETS (M CNY)NON-CURRENT ASSETS (M CNY)TOTAL ASSETS (B CNY)LIABILITIESCOMMON STOCK (k CNY)ADDITIONAL PAID-IN CAPITAL (B CNY)RETAINED EARNINGS (M CNY)OTHER EQUITY (M CNY)UNREAL. GAINS/LOSSES (M CNY)EQUITY (B CNY)LIABILITIES (M CNY)PROVISIONS (M CNY)OTHER SHORT-TERM LIAB. (M CNY)SHORT-TERM DEBTS (M CNY)LONG-TERM DEBT PORTION (M CNY)SHORT-TERM REC. (M CNY)LONG-T. LIAB. (B CNY)DEFERRED TAXES (M CNY)OTHER LIAB. (M CNY)LONG-T. LIABILITIES (B CNY)DEBT (B CNY)TOTAL CAPITAL (B CNY)
201720182019202020212022
           
0.290.10.261.520.790.33
14.340.684.8165.7289.9257.8
2.56.20.6-0.30.1-6.7
12.821.617.92535.642.4
42.961.663.779.6131.181.7
0.370.230.431.791.250.71
65.382.6126.2136.6162.4177.6
00019.649.850.5
000000
3.93.45.512.320.732.1
000000
4.97.812.715.437.66.2
74.193.8144.4183.9270.5266.4
0.440.320.571.971.520.98
           
000100100100
0.040.0406.666.716.73
-649-1,093.2-1,774.8-4,965.1-5,505.7-6,188.8
000000
000000
-0.61-1.06-1.771.691.210.55
42.258.9159.7145.3213249
000000
3.48.918.28.4129.6
000015.286
0034.975.22545.2
45.667.8212.8228.9265.2389.8
1.021.322.140.050.030.03
000000
00008.69.8
1.021.322.140.050.040.04
1.061.392.350.280.310.43
0.450.330.581.971.510.97
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Genetron Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Genetron Holdings's financial health and stability.

Assets

Genetron Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Genetron Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Genetron Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Genetron Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CNY)DEPRECIATION (M CNY)DEFERRED TAXES (M CNY)CHANGES IN WORKING CAPITAL (M CNY)NON-CASH ITEM (B CNY)PAID INTEREST (M CNY)PAID TAXES (M CNY)NET CASH FLOW FROM OPERATING ACTIVITIES (M CNY)CAPITAL EXPENDITURES (M CNY)CASH FLOW FROM INVESTING ACTIVITIES (M CNY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CNY)INTEREST INCOME AND EXPENSES (M CNY)NET DEBT CHANGE (M CNY)NET CHANGE IN EQUITY (B CNY)CASH FLOW FROM FINANCING ACTIVITIES (B CNY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (CNY)TOTAL DIVIDENDS PAID (M CNY)NET CHANGE IN CASH FLOW (B CNY)FREE CASH FLOW (M CNY)SHARE-BASED COMPENSATION (M CNY)
201720182019202020212022
-420-465-676-3,069-502-810
202731536377
000000
-17-2062-124-15173
0.310.290.422.870.120.22
005446
000000
-129-201-197-300-524-460
-21-47-25-50-85-82
-198171-96-84-136-87
-176218-71-34-50-5
000000
602325-4397
0.350.060.361.7400
0.350.050.371.74-0.060.07
-4.00-10.00-10.00-23.00-16.00-26.00
000000
0.020.020.081.24-0.74-0.46
-151.2-248.4-222.6-350.9-610-542.3
000000

Genetron Holdings stock margins

The Genetron Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genetron Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genetron Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Genetron Holdings's sales revenue. A higher gross margin percentage indicates that the Genetron Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Genetron Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Genetron Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genetron Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genetron Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genetron Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Genetron Holdings Margin History

Genetron Holdings Gross marginGenetron Holdings Profit marginGenetron Holdings EBIT marginGenetron Holdings Profit margin
2026e43.25 %-29.18 %-63.96 %
2025e43.25 %-34.16 %-50.47 %
2024e43.25 %-43 %-42.94 %
2023e43.25 %-69.5 %-69.59 %
202243.25 %-108.13 %-124.24 %
202163.53 %-100.13 %-93.27 %
202061.3 %-60.49 %-722.97 %
201944.84 %-94.81 %-209.03 %
201841.16 %-106.31 %-206.48 %
201726.53 %-152.57 %-416.44 %

Genetron Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Genetron Holdings earnings per share therefore indicates how much revenue Genetron Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genetron Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genetron Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genetron Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genetron Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genetron Holdings Revenue, EBIT and net profit per share

DateGenetron Holdings Sales per ShareGenetron Holdings EBIT per shareGenetron Holdings Earnings per Share
2026e2.97 CNY0 CNY-1.9 CNY
2025e2.43 CNY0 CNY-1.23 CNY
2024e1.98 CNY0 CNY-0.85 CNY
2023e1.6 CNY0 CNY-1.11 CNY
20224.21 CNY-4.55 CNY-5.23 CNY
20213.47 CNY-3.47 CNY-3.23 CNY
20204.22 CNY-2.56 CNY-30.54 CNY
20197.77 CNY-7.37 CNY-16.25 CNY
20185.94 CNY-6.32 CNY-12.27 CNY
20173.34 CNY-5.1 CNY-13.93 CNY

Genetron Holdings business model

Genetron Holdings Ltd is a Chinese company that focuses on the development of discoveries in genomic research. They are known for their advanced technologies that allow for the development of cancer diagnostics and personalized therapies. History: Genetron was founded in 2015 by Sizhen Wang, a leading expert in the field of molecular diagnostics. Since then, the company has experienced rapid growth and has become a well-known name in genomic research. In 2019, Genetron Holdings went public on the Beijing Star Board of the Chinese stock exchange. Business model and divisions: The company is divided into two main activities - diagnostics and research. In the diagnostics division, the company focuses on developing personalized medicines for cancer patients. Genetron works closely with hospitals and research institutions throughout China to develop diagnostic tools for cancer prevention. In the research department, the company is involved in the discovery of new genetic markers for various diseases. Genetron utilizes state-of-the-art technologies such as Crispr-Cas9 to edit genes and determine which genes are responsible for which diseases. Products and services: Genetron offers a range of products and services for cancer diagnostics. One of their most well-known products is the Genetron Health System, a platform for personalized medicine. The system uses genetic profiles to identify the best treatment options for patients. Genetron also offers a variety of other diagnostic tests, including tests for ovarian cancer, lung cancer, and stomach cancer. The company also offers a variety of research services. These include genetic studies, the discovery of new medical therapies, and collaboration with other companies in the field of genomic research. Conclusion: Genetron Holdings Ltd is a company with a fascinating history and a unique business model. Their dedication to innovative cancer diagnostics and personalized medicine has helped them become leaders in genomic research. The company offers a wide range of products and services and works closely with the medical community to improve the health and well-being of patients. Genetron Holdings is one of the most popular companies on Eulerpool.com.

Genetron Holdings SWOT Analysis

Strengths

  • Strong reputation in the genetic testing industry
  • Advanced technology and innovative products
  • Well-established partnerships with leading medical institutions

Weaknesses

  • Relatively small market share compared to key competitors
  • Limited international presence
  • Dependency on a few key products

Opportunities

  • Growing demand for genetic testing services
  • Expansion into new geographic markets
  • Increasing government support for precision medicine

Threats

  • Intense competition from larger and established companies
  • Regulatory challenges in different markets
  • Technological advancements by competitors

Genetron Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Genetron Holdings historical P/E ratio, EBIT, and P/S ratio.

Genetron Holdings shares outstanding

The number of shares was Genetron Holdings in 2023 — This indicates how many shares 154.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genetron Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genetron Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genetron Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genetron Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genetron Holdings Stock splits

In Genetron Holdings's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Genetron Holdings.

Genetron Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2022-0.67 CNY-7.35 CNY (-992.61 %)2022 Q2
3/31/2021-3.62 CNY-3.31 CNY (8.58 %)2021 Q1
12/31/2020-1.57 CNY-1.99 CNY (-26.87 %)2020 Q4
9/30/2020-0.52 CNY-0.48 CNY (6.5 %)2020 Q3
6/30/2020-0.61 CNY-1.35 CNY (-120.19 %)2020 Q2
1

Genetron Holdings list of shareholders

%
Name
Stocks
Change
Date
0.03454 % Black Maple Capital Management LP158,112158,11212/31/2023
0.03243 % Jiao (Yuchcn)148,43360,0003/31/2023
0.02477 % Crystalline Management, Inc.113,395113,39512/31/2023
0.02345 % Yong Rong (HK) Asset Management Limited107,360-112/31/2023
0.01994 % Robeco Institutional Asset Management B.V.91,293-112/31/2023
0.01949 % Renaissance Technologies LLC89,22738,52712/31/2023
0.01930 % Robeco Hong Kong Limited88,33302/29/2024
0.01789 % JBF Capital, Inc.81,90081,90012/31/2023
0.00597 % Susquehanna International Group, LLP27,34927,34912/31/2023
0.00379 % Rhumbline Advisers Ltd. Partnership17,352-4,83612/31/2023
1
2
3
4
5
...
7

Most common questions regarding Genetron Holdings

What values and corporate philosophy does Genetron Holdings represent?

Genetron Holdings Ltd represents values of innovation, integrity, and collaboration. With a corporate philosophy centered on advancing precision oncology through technology, Genetron is dedicated to transforming cancer diagnosis and treatment. The company strives to improve patient outcomes by developing and commercializing cutting-edge molecular profiling assays and solutions. Through its comprehensive genomic testing platforms, Genetron aims to empower physicians and researchers to make informed decisions for personalized cancer care. By leveraging its expertise in next-generation sequencing and advanced data analysis, Genetron is committed to driving advancements in precision medicine and contributing to the global fight against cancer.

In which countries and regions is Genetron Holdings primarily present?

Genetron Holdings Ltd is primarily present in China.

What significant milestones has the company Genetron Holdings achieved?

Genetron Holdings Ltd, a renowned company in the field of genomics and precision oncology, has achieved remarkable milestones throughout its journey. Firstly, the company successfully developed the Genetron S5, an innovative sequencing system, enabling high-quality genetic testing and analysis for cancer patients. Secondly, Genetron Holdings established strategic collaborations with reputable medical institutions, such as the Mayo Clinic and the China National Cancer Center, enhancing their research capabilities and expanding their market influence. Additionally, the company obtained the CE-IVD marking for multiple molecular diagnostic products, enabling their use in European clinical practice. Furthermore, Genetron Holdings gained recognition by receiving numerous awards, including the Frost & Sullivan 2021 Best Practices Award for Chinese Next-Generation Sequencing Solutions Company of the Year. These milestones exemplify the company's commitment to revolutionizing cancer diagnosis and treatment through cutting-edge genomics technology.

What is the history and background of the company Genetron Holdings?

Genetron Holdings Ltd is a prominent biotechnology company that specializes in precision oncology. Founded in 2015, the company has quickly gained recognition for its innovative approach to cancer treatment. As a leading player in the field, Genetron has developed advanced molecular profiling technology and diagnostic solutions to aid in personalized cancer care. With a team consisting of experienced professionals, Genetron focuses on harnessing the power of genomics to revolutionize cancer treatment and improve patient outcomes. By leveraging cutting-edge technologies and strategic collaborations, Genetron Holdings Ltd continues to make significant contributions to the field of precision medicine.

Who are the main competitors of Genetron Holdings in the market?

The main competitors of Genetron Holdings Ltd in the market include Illumina Inc., Thermo Fisher Scientific Inc., and Qiagen N.V.

In which industries is Genetron Holdings primarily active?

Genetron Holdings Ltd is primarily active in the healthcare and biotechnology industries.

What is the business model of Genetron Holdings?

Genetron Holdings Ltd is a leading precision oncology company that focuses on providing innovative solutions for cancer diagnosis and treatment. The company's business model revolves around its advanced molecular profiling technology, which enables personalized cancer therapy and enables better patient outcomes. By utilizing cutting-edge techniques such as next-generation sequencing and artificial intelligence, Genetron Holdings Ltd aims to revolutionize cancer care by offering accurate and reliable genomic profiling services. Through its comprehensive portfolio of products and services, the company is committed to empowering healthcare professionals with actionable insights to make informed treatment decisions and improve patient care.

What is the P/E ratio of Genetron Holdings 2024?

The Genetron Holdings P/E ratio is -11.59.

What is the P/S ratio of Genetron Holdings 2024?

The Genetron Holdings P/S ratio is 4.97.

What is the AlleAktien quality score of Genetron Holdings?

The AlleAktien quality score for Genetron Holdings is 4/10.

What is the revenue of Genetron Holdings 2024?

The expected Genetron Holdings revenue is 904.47 M CNY.

How high is the profit of Genetron Holdings 2024?

The expected Genetron Holdings profit is -388.35 M CNY.

What is the business model of Genetron Holdings

Genetron Holdings Ltd is a China-based company specialized in the development of precision medicine products and services. The company offers a variety of solutions for clinicians, researchers, and medical institutions. Genetron operates in three business segments: Liquid Biopsy, Oncology Testing Services, and Cancer Genomics. Liquid Biopsy: Genetron's Liquid Biopsy business segment provides a non-invasive method for detecting cancer cells through liquid biopsies. The company has a proprietary technology platform for examining minimal residual disease in patients. This technology is used to examine biological materials such as blood and urine for cancer cells and other cellular irregularities. The results are then used for diagnosis and disease monitoring. Oncology Testing Services: Genetron's Oncology Testing Services enable doctors to create personalized treatment plans for cancer patients. The company offers a wide range of testing services, including whole exome sequencing, RNA sequencing, genome-wide methylation analysis, and protein analysis. The company utilizes next-generation technologies to identify and characterize the molecular features of cancer cells. These tests help doctors create tailored treatment plans based on the specific genetic differences of each patient. Cancer Genomics: Genetron is a leading provider of cancer genomics technologies and services. The company offers a range of solutions that enable researchers and medical institutions to collect and analyze cancer genomic data. The company's core technologies include whole exome sequencing, transcriptome sequencing, and splice variant sequencing. These technologies allow researchers to identify and characterize the molecular features of cancer cells. The results of these analyses are used to develop personalized treatment options and explore new therapies. Summary: Overall, Genetron Holdings Ltd offers a comprehensive range of products and services in the field of precision medicine. The company is a leader in Liquid Biopsy, Oncology Testing Services, and Cancer Genomics. Genetron's technologies and services enable doctors and researchers to identify, characterize, and develop personalized treatment options for cancer cells. The company is well-positioned to benefit from the growing demand for precision medicine products and services.

What is the Genetron Holdings dividend?

Genetron Holdings pays a dividend of 0 CNY distributed over payouts per year.

How often does Genetron Holdings pay dividends?

The dividend cannot currently be calculated for Genetron Holdings or the company does not pay out a dividend.

What is the Genetron Holdings ISIN?

The ISIN of Genetron Holdings is US37186H1005.

What is the Genetron Holdings WKN?

The WKN of Genetron Holdings is A2P661.

What is the Genetron Holdings ticker?

The ticker of Genetron Holdings is GTH.

How much dividend does Genetron Holdings pay?

Over the past 12 months, Genetron Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genetron Holdings is expected to pay a dividend of 0 CNY.

What is the dividend yield of Genetron Holdings?

The current dividend yield of Genetron Holdings is .

When does Genetron Holdings pay dividends?

Genetron Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genetron Holdings?

Genetron Holdings paid dividends every year for the past 0 years.

What is the dividend of Genetron Holdings?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genetron Holdings located?

Genetron Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genetron Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genetron Holdings from 9/12/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Genetron Holdings pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of Genetron Holdings in the year 2023?

In the year 2023, Genetron Holdings distributed 0 CNY as dividends.

In which currency does Genetron Holdings pay out the dividend?

The dividends of Genetron Holdings are distributed in CNY.

All fundamentals about Genetron Holdings

Our stock analysis for Genetron Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genetron Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.